EA201390197A1 - Применение hmgb1 в качестве биологического маркера воспалительных состояний кишечника, неинвазивный способ его определения в образцах фекалий и набор для этого - Google Patents

Применение hmgb1 в качестве биологического маркера воспалительных состояний кишечника, неинвазивный способ его определения в образцах фекалий и набор для этого

Info

Publication number
EA201390197A1
EA201390197A1 EA201390197A EA201390197A EA201390197A1 EA 201390197 A1 EA201390197 A1 EA 201390197A1 EA 201390197 A EA201390197 A EA 201390197A EA 201390197 A EA201390197 A EA 201390197A EA 201390197 A1 EA201390197 A1 EA 201390197A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hmgb1
kit
fecal
intestine
definition
Prior art date
Application number
EA201390197A
Other languages
English (en)
Russian (ru)
Inventor
Сальваторе Куккьяра
Лаура Стронати
Роберта Витали
Original Assignee
Д.М.Г. Италия Срл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Д.М.Г. Италия Срл filed Critical Д.М.Г. Италия Срл
Publication of EA201390197A1 publication Critical patent/EA201390197A1/ru

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875Nucleoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EA201390197A 2010-08-05 2011-08-01 Применение hmgb1 в качестве биологического маркера воспалительных состояний кишечника, неинвазивный способ его определения в образцах фекалий и набор для этого EA201390197A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2010A000442A IT1406051B1 (it) 2010-08-05 2010-08-05 Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
PCT/IT2011/000276 WO2012017466A1 (en) 2010-08-05 2011-08-01 Use of hmgb1 as' a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof

Publications (1)

Publication Number Publication Date
EA201390197A1 true EA201390197A1 (ru) 2013-06-28

Family

ID=43739596

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390197A EA201390197A1 (ru) 2010-08-05 2011-08-01 Применение hmgb1 в качестве биологического маркера воспалительных состояний кишечника, неинвазивный способ его определения в образцах фекалий и набор для этого

Country Status (14)

Country Link
US (1) US20130137123A1 (enExample)
EP (1) EP2601525A1 (enExample)
JP (1) JP2013534313A (enExample)
CN (1) CN103069276A (enExample)
AU (1) AU2011287193B2 (enExample)
BR (1) BR112013002145A2 (enExample)
CA (1) CA2807107C (enExample)
CL (1) CL2013000223A1 (enExample)
EA (1) EA201390197A1 (enExample)
IL (1) IL223845A (enExample)
IT (1) IT1406051B1 (enExample)
MX (1) MX2013001327A (enExample)
PE (1) PE20131062A1 (enExample)
WO (1) WO2012017466A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968443B1 (en) 2013-03-15 2021-09-29 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
EP3094973B1 (en) 2013-11-07 2020-07-29 Diagnodus Limited Biomarkers
EP3143037B1 (en) 2014-05-16 2021-06-23 Protagonist Therapeutics, Inc. Alpha4beta7 integrin thioether peptide antagonists
CN113563423A (zh) 2014-07-17 2021-10-29 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
US20200064357A1 (en) * 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
BR112019023772A2 (pt) 2017-05-12 2020-06-09 Evonik Operations Gmbh método para detectar doenças induzidas por c. perfringens em animais e kit de diagnóstico
IT201700083044A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
IT201700083055A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della proteina inibitore 2 della dissociazione di rho gdp come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
EP4501952A3 (en) 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US12031991B2 (en) 2018-03-02 2024-07-09 Evonik Operations Gmbh In vitro method for detecting intestinal barrier failure in animals
CN109030817A (zh) * 2018-07-04 2018-12-18 长沙都正医学检验有限责任公司 Hmgb1检测试剂盒及其制备方法
EP3894863B1 (en) 2018-12-14 2022-11-23 Evonik Operations GmbH In vitro method for detecting avian intestinal dysbiosis
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
BR112022014011A2 (pt) 2020-01-15 2022-12-20 Janssen Biotech Inc Inibidores peptídicos de receptor de interleucina-23 e seu uso no tratamento de doenças inflamatórias
MX2022008741A (es) 2020-01-15 2022-10-03 Janssen Biotech Inc Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
WO2022109328A1 (en) 2020-11-20 2022-05-27 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
CN116973572B (zh) * 2023-06-02 2025-03-07 东南大学附属中大医院 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0964250B1 (en) * 1996-07-17 2007-06-27 Kaneka Corporation Diagnostic drugs for autoimmune diseases
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7700307B2 (en) * 2003-03-08 2010-04-20 Auvation Limited Mitochondrial stress-70 protein markers for colorectal cancer
AU2005333602B2 (en) * 2004-10-22 2012-04-12 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
WO2008075788A1 (ja) * 2006-12-20 2008-06-26 Shino-Test Corporation ヒトhmgb1と特異的に結合する鳥類由来の抗体、ヒトhmgb1の免疫学的測定方法及びヒトhmgb1の免疫学的測定試薬
EA201000131A1 (ru) * 2007-08-02 2010-08-30 АйЭсЭс ИММЬЮН СИСТЕМ СТИМУЛЕЙШН АБ Диагностика, определение стадии и мониторинг воспалительного заболевания кишечника
WO2009114756A2 (en) * 2008-03-14 2009-09-17 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome

Also Published As

Publication number Publication date
AU2011287193A1 (en) 2013-06-13
CA2807107A1 (en) 2012-02-09
US20130137123A1 (en) 2013-05-30
CN103069276A (zh) 2013-04-24
WO2012017466A8 (en) 2013-07-11
JP2013534313A (ja) 2013-09-02
AU2011287193B2 (en) 2015-08-13
WO2012017466A1 (en) 2012-02-09
IT1406051B1 (it) 2014-02-06
CL2013000223A1 (es) 2014-03-28
EP2601525A1 (en) 2013-06-12
PE20131062A1 (es) 2013-10-16
ITRM20100442A1 (it) 2012-02-06
IL223845A (en) 2016-06-30
BR112013002145A2 (pt) 2016-05-24
MX2013001327A (es) 2013-03-08
CA2807107C (en) 2017-01-03

Similar Documents

Publication Publication Date Title
EA201390197A1 (ru) Применение hmgb1 в качестве биологического маркера воспалительных состояний кишечника, неинвазивный способ его определения в образцах фекалий и набор для этого
MA46219B1 (fr) Composés de co-agonistes du glucagon et du glp-1
UA109633C2 (uk) Антитіло людини проти тканинного фактора
Kofla-Dłubacz et al. Metalloproteinase-3 and-9 as novel markers in the evaluation of ulcerative colitis activity in children
UY32477A (es) Proteínas de unión a il-17
IL225386A0 (en) Diagnosis and treatment of cancer using anti-ereg antibody
BR112012028920A2 (pt) formulações de anticorpo de alta concentração
EA201590523A1 (ru) Il-18-связывающие молекулы
EA201000424A1 (ru) Антитела к il-23
WO2010060102A3 (en) Prediction and prevention of preeclampsia
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
BRPI0712273A2 (pt) Anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit
WO2011112670A3 (en) Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease
BR112012028010A2 (pt) anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
EP2420515A4 (en) DIAGNOSIS AND TREATMENT OF CANCER WITH ANTI-TMPRSS11E ANTIBODY
FR2896588B1 (fr) Methode de diagnostic in vitro de reponse immunitaire autoimmune par detection d'anticorps diriges contre l'antigene pentraxine 3.
EP2243829A4 (en) IMPROVED HUMANIZED ANTI-HUMAN 9-INTEGRIN ANTIBODY
WO2014169011A3 (en) Methods for treating immune diseases
EP1870711A4 (en) MARKER PROTEIN FOR USE IN THE DIAGNOSIS OF PANCREATIC CANCER
PL408905A1 (pl) Nowy związek, sposób jego otrzymywania, roztwór farmaceutyczny zawierający nowy związek, sposób określania obecności choroby nowotworowej, zestaw do wykrywania nowotworów oraz zastosowanie hydrolizy nowego związku do wykrywania nowotworów
FR2968767B1 (fr) Procede et coffret pour le diagnostic in vitro du cancer de la prostate
FR2930036B1 (fr) Procede de diagnostic d'une hypertension arterielle pulmonaire.
FR2900936B1 (fr) Procede et methodes de detection de la maladie d'alzheimer
EP1769244A4 (en) DETECTION OR MEASUREMENT OF ANTIGEN PROTEIN ANTIBODIES IN BIOLOGICAL TISSUE OR SAMPLES
BRPI1014743A2 (pt) "detecção de sangue oculto nas fezes ou urina"